The use of triptans during pregnancy does not appear to increase rates for major congenital malformations (MCM) or prematurity, but may increase rates of spontaneous miscarriage, according to a meta-analysis of 6 studies including 4,208 triptan-exposed pregnancies and 1.5 million controls.
Compared with women with migraine who did not use triptans during pregnancy, triptan use was not associated with increased rates for MCM, prematurity, or miscarriage.
Compared to healthy controls, however, researchers noted a significant increase in miscarriage. In addition, the migraine no-triptan group also had higher rates of MCMs compared to healthy controls.
Citation: Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache. 2015. doi: 10.1111/head.12500.